An observational study in Papillary Thyroid Microcarcinoma, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by European Institute of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)
Image-guided thermal ablations have been successfully applied in the treatment of several type of tumors, and have been recently proposed as a potential alternative to surgery also in patients with thyroid diseases, and named "Minimally Invasive Treatments of the Thyroid (MITT)". These minimally invasive treatments, compared to surgical treatment have similar efficacy, fewer complications, better quality of life, and better cosmetic outcomes. These procedures allow precise delivery of the heat locally to the lesion, sparing the surrounding thyroid tissue, and thus minimizing the invasiveness of the treatment and the impact on thyroid function.
This study aim to establish a prospective registry of the cases of patients treated with MITT for a Papillary Thyroid MicroCarcinoma (PTMC), in order to validate the safety of the procedure and to set the basis for collecting long term results in a large cohort of patients.
24 studies on the registry are indexed under Papillary Thyroid Microcarcinoma; 8 are open to participants now.
This study's planned enrollment of 270 is below the median of 480 across 15 observational studies indexed under Papillary Thyroid Microcarcinoma.
Browse Papillary Thyroid Microcarcinoma studies →European Institute of Oncology is the lead sponsor of 186 studies on the registry; 118 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with thyroid diseases suitable for "Minimally Invasive Treatments of the Thyroid (MITT)" as potential alternative to surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
Procedure: image-guided thermal ablation
image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
The proportion of patients with major complications occurring within one month after the date of intervention
Complications will be reported according to modified Society of Interventional Radiology (SIR) classification
Time frame: 1 month
Percentage of patients with local recurrence at 10 years
Evaluation of disease free survival (DFS): percentage of patient whith a local recurrence at 10 years of follow up
Time frame: 10 years
Percentage of patients with distant metastasis at 10 years
Evaluation of disease free survival (DFS): percentage of patient whith distant metastasis at 10 years of follow up
Time frame: 10 years
Percentage of patients died at 10 years
Evaluation of Overall Survival (OS): Percentage of patients died at 10 years
Time frame: 10 years
Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Papillary Thyroid Microcarcinoma →
European Institute of Oncology →